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Abstract 48 
Purpose 49 
Clinical guidelines recommend at least seven days of antibiotic treatment for older 50 
men with urinary tract infection (UTI). There may be potential benefits for patients, 51 
health services and antimicrobial stewardship if shorter antibiotic treatment resulted in 52 
similar outcomes. We aimed to determine if treatment duration could be reduced by 53 
estimating risk of adverse outcomes according to different prescription durations. 54 
Methods 55 
This retrospective cohort study included men aged ≥65 years with a suspected UTI. 56 
We compared outcomes in men prescribed 3, 5, 7 and 8-14 days of antibiotic treatment 57 
in a multivariable logistic regression analysis, and 3 versus 7 days in a propensity-58 
score matched analysis. Our outcomes were re-consultation and re-prescription 59 
(proxy for treatment failure), hospitalisation for UTI, sepsis, or acute kidney injury 60 
(AKI), and death.  61 
Results  62 
Of 360,640 men aged ≥65 years, 33,745 (9.4%) had a UTI. Compared to 7-days, men 63 
prescribed 3-day treatment had greater odds of re-consultation and re-prescription 64 
(adjusted OR 1.48, 95% CI 1.25-1.74) but lower odds of AKI hospitalisation (adjusted 65 
OR 0.66, 95% CI 0.45-0.97). We estimated that treating 150 older men with 3-days 66 
instead of 7-days of antibiotics could result in four extra re-consultation and re-67 
prescriptions and one less AKI hospitalisation. We estimated annual prescription cost 68 
savings at around £2.2 million.  69 
Conclusions  70 
4 
 
Antibiotic treatment for older men with suspected UTI could be reduced to 3-days, 71 
albeit with a small increase in risk of treatment failure. A definitive randomised trial is 72 
urgently needed. 73 
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Main text 95 
Introduction 96 
Urinary tract infections (UTIs) represent an important cause of morbidity and antibiotic 97 
use in older men. Around 20% of all UTIs occur in men.1 Incidence increases with age 98 
from around 3 episodes per 100 person-years in men aged 65-74, to 8-11 episodes 99 
per 100 person-years in men aged ≥85.2, 3  100 
The optimal duration of antibiotic treatment for UTI in older men is not known.4  Most 101 
clinical guidelines recommend seven days of antibiotic treatment.5-7 This 102 
recommendation is largely based on expert consensus due to the lack of data in this 103 
area. Previous randomised trials investigating different antibiotic durations for UTI in 104 
men have focussed on febrile 8, 9 or complicated UTI,10, 11 or men with spinal cord 105 
injury,12 and are not generalizable to the majority of men with community-acquired UTI 106 
seen and treated in primary or ambulatory care settings.  107 
Antimicrobial stewardship policies and guidelines recommend prescribing the 108 
minimum duration of antibiotic treatment required for clinical resolution.13, 14 Two 109 
recent studies indicate that antibiotic treatment duration for UTI in older men could be 110 
reduced. First, a retrospective study of UK health records found that around 20% of 111 
older men presenting to primary care with a UTI were prescribed <7 days of antibiotics, 112 
suggesting that some clinicians may already be prescribing shorter treatment to 113 
selected men.2 Second,    an observational study found no difference in the rate of 114 
clinical recurrence between US male Veterans with UTI prescribed long course (>7 115 
days) versus short course treatment (≤7 days).15 However, this study used outpatient 116 
data only and therefore may have missed men who were subsequently hospitalised 117 
with UTI-related emergencies, such as sepsis or acute kidney injury. 118 
6 
 
We therefore used anonymised linked health records that spanned primary care, 119 
secondary care and death registry data, to estimate risk of adverse outcomes in older 120 
men prescribed different durations of antibiotic treatment for UTI in primary care. Our 121 
aim was to assess whether short course treatment was associated with an increased 122 
risk of adverse events to determine the potential for safe and effective reduction of 123 
antibiotic treatment duration.  124 
Patients and Methods 125 
Data Source 126 
We used the Clinical Practice Research Datalink (CPRD), an electronic database of 127 
anonymised primary care records, covering 11.3 million patients from 674 general 128 
practices across the UK.16 Approximately 7% of the UK population are included and 129 
patients are broadly representative of the wider UK population in terms of age, gender 130 
and ethnicity. The CPRD holds data on demographics, clinical encounters and 131 
diagnoses (coded using Read codes), drug prescriptions, laboratory tests and referrals 132 
to specialists. Data are available once the primary care records have met a series of 133 
quality checks on completeness and reliability and the CPRD deems them to be of a 134 
required standard for research purposes. Linked hospital and death registration data 135 
are available for patients from approximately 50% of contributing English practices. 136 
Hospital diagnoses and causes of death are recorded using version 10 of the 137 
International Classification of Disease (ICD-10). 138 
The CPRD Independent Scientific Advisory Committee approved the study protocol 139 
(protocol number 17_250). Further ethical approval was not required as the proposed 140 
research was within the remit of the CPRD’s broad National Research Ethics Service 141 
approval. We used the Reporting of Studies Conducted using Observational 142 
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Routinely-collected Health Data (RECORD) statement and checklist to guide study 143 
reporting.17  144 
Design and participants 145 
This was a retrospective cohort study using linked health record data. Men were 146 
eligible for inclusion if, between 1st January 2010 and 31st December 2016, their data 147 
were of the quality required by CPRD, they were ≥65 years old, were registered with 148 
a practice that had consented to linkage to hospital and death registry data, and had 149 
a primary care record of an incident UTI. Follow-up began from the latest of, study 150 
start date (1st January 2010), patient’s 65th birthday, six months after they registered 151 
with the practice (to avoid including historical UTIs recorded at registration), or the 152 
date their practice met the CPRD data quality requirements. Follow-up ended on the 153 
earliest of study end date (31st December 2016), the day the patient died or transferred 154 
out of the practice (i.e. last date of CPRD data collection), or 28 days after an incident 155 
UTI event. We excluded men who were temporary residents, or had gaps in their data 156 
coverage. We defined ‘incident’ as an event occurring in a man without a UTI-related 157 
Read code or trimethoprim or nitrofurantoin prescription in the preceding 90 days. We 158 
defined UTI as the presence of a symptom code (e.g., “dysuria”) or diagnostic code 159 
(e.g., “cystitis”) relevant to UTI (codes available in Supplementary Appendix 1), and a 160 
same-day prescription code indicating prescribing of a relevant antibiotic. We 161 
restricted the analyses to the first incident UTI identified during a patient’s follow-up 162 
period. 163 
Exposure 164 
We used prescription data for daily dosing and total quantity prescribed to calculate 165 
duration of antibiotic prescriptions as a proxy for duration of treatment. We excluded 166 
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prescriptions with durations >14 days as it is unlikely that these were prescribed for 167 
an acute UTI, and more likely that they reflected treatment for prostatitis. We also 168 
excluded prescription durations of 1, 2, 4, and 6 days, as together these represented 169 
<1% of all calculated durations and were potentially unreliable. The final exposure 170 
groups were 3, 5, 7 and 8-14 days. 171 
Outcomes 172 
We assessed the impact of antibiotic prescription duration on: 173 
1. Re-consultation for urinary symptoms and a same-day antibiotic prescription 174 
within 14 days following the incident UTI, as a proxy for treatment non-175 
response, ascertained through Read and prescription codes recorded in 176 
primary care records. 177 
2. Hospitalisation for UTI, sepsis, or acute kidney injury (AKI) within 14 days 178 
following the incident UTI ascertained from ICD-10 codes recorded in linked 179 
hospital admission data for the first episode of a hospital admission, i.e., the 180 
episode most likely responsible for the admission. 181 
3. Death within 28 days following the incident UTI using linked death registration 182 
data. 183 
Statistical Analyses 184 
We used primary care demographic and clinical codes to describe baseline 185 
characteristics for patients by prescription duration. Firstly, we assessed the impact of 186 
different prescription durations by calculating odds ratios (OR) and 95% confidence 187 
intervals (CI) for the risk of each outcome in those prescribed 7-day treatment, 188 
compared to  those prescribed 3, 5 or 8-14 days treatment. We adjusted for potential 189 
confounders of the association between antibiotic duration and outcome, including the 190 
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choice of antibiotic, age, Index of Multiple Deprivation score quintile, Charlson 191 
comorbidity score,  polypharmacy (defined as records indicating ≥5 long-term 192 
medications per month in the year prior to the incident UTI), and the presence or 193 
absence of a record indicating diabetes, dementia, coronary heart disease, stroke, 194 
cancer, heart failure, renal disease, benign prostatic hyperplasia, and prostate cancer.  195 
Secondly, we compared outcomes in men prescribed 3-day versus 7-day treatment 196 
using propensity score matching to improve balance of baseline covariates across the 197 
two treatment groups. We chose 7 days as the reference standard as it is currently the 198 
recommended treatment duration for male UTI in the UK, and 3 days as the 199 
comparator as it is a potentially acceptable and feasible shorter duration of treatment, 200 
given that 3-day treatment is widely used to treat UTI in women. Men were matched 201 
on a range of demographic and clinical variables related to their propensity to receive 202 
a 7-day prescription. We used nearest neighbour matching with no replacement and 203 
matched each patient with a 3-day prescription to three patients with a 7-day 204 
prescription. We assessed balance in measured baseline covariates between 205 
matched groups by visually inspecting jitter plots and histograms of covariate 206 
distribution before and after matching, and by calculating standardised mean 207 
differences for covariates between groups. We regarded standardised mean 208 
differences of <0.1 as reflecting adequate balance.18, 19   209 
We used mixed effects models in both analyses to account for clustering by general 210 
practice. We repeated the analyses restricting to men prescribed trimethoprim, the 211 
most commonly used antibiotic for UTI in the UK during the study period. Finally, we 212 
calculated E-values to estimate the minimum effect size required by an unmeasured 213 
confounder to fully explain away any statistically significant associations.20  All 214 
statistical tests were 2-sided with p<0.05 considered statistically significant but an 215 
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effect size of 10% considered clinically significant. Analyses were conducted in R 216 
version 3.2.1. 217 
Results 218 
From a cohort of 360,640 men aged 65 and over with a median follow-up of 4.9 years 219 
(Interquartile range (IQR), 3.1-6.4), we identified 33,745 (9.4%) with an incident UTI 220 
treated with a relevant antibiotic (Figure 1). Of these, we were able to assign an 221 
antibiotic prescription duration to 32,593 (96.6%) incident UTIs. The median age at the 222 
time of incident UTI was 77 years (IQR, 70 - 83). In total, 1966 (6.0%) men were 223 
prescribed amoxicillin, 2002 (6.1%) ciprofloxacin, 2060 (6.3%) cefalexin, 2143 (6.6%) 224 
co-amoxiclav, 5724 (17.6%) nitrofurantoin, and 18,698 (57.4%) trimethoprim. 225 
Guideline concordant 7-day treatment was prescribed to 20,729 (63.6%) men, 3-day 226 
treatment to 2498 (7.7%), 5-day treatment to 6254 (19.2%), and 8-14 days to 3112 227 
(9.5%). Practices varied in their prescribing of the different antibiotic durations. Of all 228 
antibiotic prescriptions for UTI in older men, the median proportion prescribed 3-day 229 
treatment was 5.1% (IQR, 1.8-10.8), 5-day treatment was 14.6% (IQR, 7.7-25.4), 7-230 
day treatment was 65.4% (IQR, 53.1-76.2), and >7day treatment was 8.3% (IQR, 3.8-231 
14.8). Baseline comorbidities were broadly similar across the different treatment 232 
duration groups (Table 1).   233 
Outcomes according to treatment duration 234 
A total of 2007 (6.2%) men re-consulted and received another antibiotic prescription 235 
within 14 days following the incident UTI. Compared to 7-day prescriptions, there was 236 
a graded association between prescription duration and odds of re-consultation and 237 
re-prescription with adjusted ORs of 1.48 (95% CI 1.25-1.74) for 3-day prescriptions, 238 
1.18 (95% CI 1.04-1.33) for 5-day prescriptions, and 0.80 (95% CI 0.67-0.96) for 8-14 239 
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day prescriptions (Table 2). The re-prescribed antibiotics were made up of a lower 240 
proportion of trimethoprim, similar proportion of amoxicillin, and greater proportions of 241 
the other antibiotics (Supplementary Table 1).  242 
A total of 817 (2.5%) men were hospitalised for UTI, 89 (0.3%) hospitalised for sepsis, 243 
and 449 (1.4%) hospitalised for AKI within 14 days following the incident UTI. There 244 
were no significant associations between antibiotic prescription duration and 245 
hospitalisation for UTI or sepsis. Compared to 7-days, 3 and 8-14 day prescriptions 246 
were associated with reduced odds of hospitalisation for AKI (adjusted OR for 3-days, 247 
0.66, 95% CI 0.45-0.97, adjusted OR for 8-14 days, 0.63, 95% CI 0.40-0.99). A total 248 
of 419 (1.3%) men died within 28 days of the incident UTI. There were no significant 249 
associations between antibiotic prescription duration and odds of death. 250 
Propensity score matched comparison of 7-day versus 3-day therapy 251 
We matched 2392 men prescribed 3-day treatment to 7182 men prescribed 7-day 252 
treatment. Inspection of jitter plots and histograms suggested matching had improved 253 
balance of covariates across the two groups. Standardised mean differences were all 254 
less than 0.1 (Table 3). 3-day prescriptions were associated with increased odds of 255 
re-consultation and re-prescription (OR 1.52, 95% CI 1.25-1.85) and reduced odds of 256 
hospitalisation for AKI (OR 0.62, 95% CI 0.42-0.93) (Table 4).    257 
Using the propensity score matched event rates and ORs in table 4, we estimate that 258 
treating 150 older men with 3-day instead of 7-day treatment, could result in four extra 259 
re-consultation and re-prescriptions (numbers needed to harm = 37) and one less AKI 260 
hospital admission (numbers needed to treat = 148).22  Our previous study showed 261 
that around 7% of a sample of roughly 400,000 men ≥65 were prescribed an antibiotic 262 
in primary care for UTI in 2014.2 Current UK population estimates suggest there are 263 
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around 5.2 million men aged ≥65.23 A 7% annual UTI rate equates to around 364,000 264 
UTI events. Based on current prescribing costs reported in the British National 265 
Formulary (3-day trimethoprim = £3.60, 7-day trimethoprim = £10.00, 7-day 266 
nitrofurantoin = £9.50), if all men were prescribed 3-days of trimethoprim instead of 7 267 
days, and men who re-consulted were prescribed 7 days of nitrofurantoin, the UK 268 
health service could save around £2.2 million a year.  269 
Sensitivity analyses 270 
We repeated the analyses restricting to men who received trimethoprim and found that 271 
all ORs were consistent with our main analyses. We calculated E-values for the two 272 
significant associations in our propensity-score matched analysis. The E-value was 273 
2.4 for re-consultation and re-prescription, and 2.6 for AKI hospitalisation, suggesting 274 
any unmeasured confounder would require an OR of at least 2.4 for its association 275 
with antibiotic prescription duration and outcome, independent of measured 276 
confounders, to explain away the observed associations.  277 
Discussion 278 
We showed, for the first time, that in older men presenting to primary care with a UTI, 279 
3-day antibiotic treatment was associated with a 52% increase in odds of re-280 
consultation and re-prescription that may indicate treatment failure or recurrent 281 
infection, but was not associated with increased odds of UTI-related hospitalisation or 282 
death. We also showed for the first time, an association between 3-day treatment and 283 
a 38% reduction in the odds of hospitalisation for AKI. 284 
Results in context 285 
A retrospective observational study of 33,336 index UTIs in US male Veterans found 286 
no difference in recurrence rates at 30 days between short and long duration antibiotic 287 
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treatment.15 Similar to our study, patients did not require microbiological confirmation 288 
of UTI and were included if they had a relevant diagnostic code and antibiotic 289 
prescription. However, this study defined ‘short duration’ as ≤7 days, and 77% of the 290 
short duration group received 7-day treatment. Thus, their comparison was ≤7 days 291 
versus >7 days, and explains the discrepancy between our finding of increased odds 292 
of re-consulting and receiving another antibiotic prescription in short duration (3 or 5-293 
day) versus long duration (7-day) treatment.  294 
Our finding of an association between 3-day antibiotic treatment and reduced odds of 295 
AKI could be explained by trimethoprim prescribing. Trimethoprim is associated with 296 
hyperkalaemia and AKI in older adults. 21 In our unmatched multivariable logistic 297 
regression analysis, the risk of AKI was reduced in the group with the shortest 298 
exposure to trimethoprim (3-day treatment) and the group with the lowest proportion 299 
of trimethoprim use (8-14 day group, 16.8% prescribed trimethoprim versus 60% in 300 
the 7-day group). In our propensity-score matched analysis, 85% of men in the 3 and 301 
the 7-day treatment groups were prescribed trimethoprim, but there was again a 302 
reduced risk of AKI in the 3-day group, supporting an association between shorter 303 
trimethoprim exposure and reduced risk of AKI.  304 
Few randomised trials have investigated the potential for shorter duration of antibiotic 305 
treatment in men with UTI, and those that have focussed on more severe UTI. A 306 
Swedish trial of 114 men with febrile UTI showed similar clinical and microbiological 307 
cure rates between 14-day and 28-day antibiotic treatment.9 A randomised placebo 308 
controlled non-inferiority trial recruited men with febrile UTI from Dutch primary care 309 
and emergency departments, and showed 7-day antibiotic treatment was inferior to 310 
14-day treatment in terms of clinical cure rates 10-18 days post UTI.8 In contrast, a US 311 
trial of men and women (39% men) with complicated UTI or acute pyelonephritis 312 
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showed no difference in outcomes between those receiving 5-day versus 10-day 313 
antibiotic treatment.10 However, these trials recruited men with more severe UTI than 314 
that normally seen in a primary care setting. To the best of our knowledge, no trials 315 
have investigated the effect of short duration antibiotic treatment for men presenting 316 
to primary care with symptoms suggestive of UTI, but without fever or other signs of 317 
ascending infection. 318 
Strengths and weaknesses of this study 319 
We used data from a general practice database that is broadly representative of the 320 
UK population.16 Cohort entry was dependent on presentation and empirical treatment 321 
of UTI in primary care, and thus reduced indication bias. We also reduced indication 322 
bias by matching patients on their propensity to receive a 7-day prescription, and 323 
achieving adequate balance of covariates across treatment groups.  324 
Our study has important limitations. We attempted to capture patients presenting with 325 
UTI but had no microbiological data to support this. However, whilst a limitation, this 326 
is also more representative of clinical practice. Our estimates are based on 327 
prescription duration and may overestimate actual antibiotic consumption.  Despite 328 
careful selection of codes used to identify eligible men, differential use of codes 329 
amongst clinicians means we may have included some men who had more 330 
complicated UTI or pyelonephritis. Our finding of an increase in the rate of UTI-related 331 
re-consultation and re-prescription among men prescribed 3-day treatment may be 332 
due to planned follow-up for those prescribed shorter courses. Furthermore, whilst 333 
some of these events may represent ‘treatment failure’, others may reflect different 334 
expectations about the speed of symptom resolution. Finally, despite our design, 335 
differential coding, indication bias and residual confounding may still have affected our 336 
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findings. However, our E-values suggest residual confounders would need relatively 337 
strong associations between antibiotic duration and outcomes to alter the conclusions 338 
from our effect estimates. 339 
Conclusions 340 
Our findings suggest it may be possible to safely reduce the duration of antibiotic 341 
treatment to 3 days for older men presenting to primary care with a UTI. For patients, 342 
shorter duration treatment could mean better adherence and less side effects. Other 343 
potential benefits may include a reduction in AKI-related hospitalisations, antibiotic 344 
burden, and prescription costs. Potential harms include a possible increased risk of 345 
treatment failure. A definitive randomised trial is needed to compare short versus 346 
standard treatment duration of a specific antibiotic for UTI in men. 347 
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Tables 468 
Table 1. Baseline characteristics according to antibiotic prescription duration. Values 469 
are numbers (%) unless otherwise stated. 470 
 
Antibiotic prescription duration 
3 days 5 days 7 days 8-14 days 
Number (%) of prescriptions 2498 (7.7) 6254 (19.2) 20729 (63.6) 3112 (9.5) 
Mean (SD) age 77.4 (8.0) 77.7 (8.1) 76.9 (7.9) 76.7 (7.8) 
Antibiotic choice 
Amoxicillin 
Cefalexin 
Ciprofloxacin 
Co-amoxiclav 
Nitrofurantoin 
Trimethoprim 
 
12 (0.5) 
60 (2.4) 
38 (1.5) 
13 (0.5) 
241 (9.6) 
2134 (85.0) 
 
512 (8.2) 
262 (4.2) 
852 (13.6) 
195 (3.1) 
802 (12.8) 
3631 (58.1) 
 
1392 (6.7) 
1133 (5.5) 
649 (3.1) 
1843 (8.9) 
3301 (15.9) 
12411 (59.9) 
 
50 (1.6) 
605 (19.4) 
463 (14.9) 
92 (3.0) 
1380 (44.3) 
522 (16.8) 
Index of multiple deprivation decile 
1 or 2 (least deprived) 
3 or 4 
5 or 6 
7 or 8 
9 or 10 (most deprived) 
 
527 (21.1) 
552 (22.1) 
599 (24.0) 
427 (17.1) 
393 (15.7) 
 
1670 (26.7) 
1494 (23.9) 
1398 (22.4) 
945 (15.1) 
747 (11.9) 
 
5217 (25.2) 
5016 (24.2) 
4568 (22.0) 
3437 (16.6) 
2491 (12.0) 
 
890 (28.6) 
764 (24.6) 
655 (21.0) 
466 (15.0) 
337 (10.8) 
Housebound 101 (4.0) 251 (4.0) 641 (3.1) 107 (3.4) 
Respiratory disease 478 (19.1) 1159 (18.5) 3934 (19.0) 629 (20.2) 
Cardiac failure 178 (7.1) 438 (7.0) 1365 (6.6) 202 (6.5) 
Dementia 160 (6.4) 399 (6.4) 1080 (5.2) 158 (5.1) 
Peripheral vascular disease 218 (8.7) 573 (9.2) 1695 (8.2) 248 (8.0) 
Renal disease 620 (24.8) 1560 (24.9) 4758 (23.0) 755 (24.3) 
Rheumatoid arthritis 47 (1.9) 105 (1.7) 374 (1.8) 53 (1.7) 
Cancer 486 (19.5) 1306 (20.9) 4225 (20.4) 689 (22.1) 
Stroke 320 (12.8) 856 (13.7) 2542 (12.3) 370 (11.9) 
Diabetes 576 (23.1) 1411 (22.6) 4659 (22.5) 677 (21.8) 
Liver disease 17 (0.7) 36 (0.6) 122 (0.6) 23 (0.7) 
Ischaemic heart disease 674 (27.0) 1622 (25.9) 5347 (25.8) 811 (26.1) 
Urinary catheter 182 (7.3) 626 (10.0) 1783 (8.6) 325 (10.4) 
Urinary incontinence 184 (7.4) 496 (7.9) 1393 (6.7) 225 (7.2) 
Polypharmacy 1048 (42.0) 2462 (39.4) 7859 (37.9) 1123 (36.1) 
Benign prostatic hyperplasia 760 (30.4) 1953 (31.2) 6341 (30.6) 1033 (33.2) 
Prostate cancer 213 (8.5) 626 (10.0) 2071 (10.0) 331 (10.6) 
eGFR 
60-90 
45-59 
30-44 
15-29 
<15 
missing 
 
1569 (62.8) 
514 (20.6) 
223 (8.9) 
69 (2.8) 
19 (0.8) 
104 (4.2) 
 
3909 (62.5) 
1269 (20.3) 
563 (9.0) 
201 (3.2) 
48 (0.8) 
264 (4.2) 
 
13573 (65.5) 
4101 (19.8) 
1735 (8.4) 
478 (2.3) 
74 (0.4) 
768 (3.7) 
 
2016 (64.8) 
600 (19.3) 
280 (9.0) 
93 (3.0) 
11 (0.4) 
112 (3.6) 
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Charlson score 
0 
1 
2 
3 
4 
5 
≥6 
 
657 (26.3) 
484 (19.4) 
512 (20.5) 
334 (13.4) 
219 (8.8) 
141 (5.6) 
151 (6.0) 
 
1594 (25.5) 
1254 (20.1) 
1230 (19.7) 
902 (14.4) 
522 (8.3) 
351 (5.6) 
401 (6.4) 
 
5819 (28.1) 
4067 (19.6) 
3958 (19.1) 
2881 (13.9) 
1759 (8.5) 
1131 (5.5) 
1114 (5.4) 
 
836 (26.9) 
579 (18.6) 
613 (19.7) 
450 (14.5) 
258 (8.3) 
189 (6.1) 
187 (6.0) 
471 
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Table 2. Adjusted ORs and 95% CIs for each outcome by antibiotic prescription duration. 
 
Re-consultation and re-prescription within 14 days Number of prescriptions Number (%) of events Crude OR Adjusted OR (95% CI) p-value 
7 days [reference] 20729 1225 (5.9) 1 1  
3 days 2498 198 (7.9) 1.37 1.48 (1.25 - 1.74) <0.001 
5 days 6254 416 (6.7) 1.13 1.18 (1.04 - 1.33) 0.009 
8-14 days 3112 168 (5.4) 0.91 0.80 (0.67 - 0.96) 0.020 
Hospitalised for UTI within 14 days 
7 days [reference] 20729 543 (2.6) 1 1  
3 days 2498 61 (2.4) 0.93 0.87 (0.66 - 1.15) 0.331 
5 days 6254 147 (2.4) 0.89 0.82 (0.67 - 1.01) 0.063 
8-14 days 3112 66 (2.1) 0.81 0.81 (0.61 - 1.08) 0.152 
Hospitalised for sepsis within 14 days 
7 days [reference] 20729 53 (0.3) 1 1  
3 days 2498 4 (0.2) 0.63 0.63 (0.22 - 1.75) 0.366 
5 days 6254 13 (0.2) 0.81 0.63 (0.34 - 1.19) 0.159 
8-14 days 3112 9 (0.3) 1.13 0.85 (0.38 - 1.90) 0.700 
Hospitalised for AKI within 14 days 
7 days [reference] 20729 307 (1.5) 1 1  
3 days 2498 30 (1.2) 0.82 0.66 (0.45 - 0.97) 0.033 
5 days 6254 88 (1.4) 0.97 0.84 (0.66 - 1.08) 0.182 
8-14 days 3112 24 (0.8) 0.53 0.63 (0.40 - 0.99) 0.047 
Death within 28 days 
7 days [reference] 20729 252 (1.2) 1 1  
3 days 2498 37 (1.5) 1.22 1.12 (0.78 - 1.61) 0.522 
5 days 6254 89 (1.4) 1.17 1.01 (0.78 - 1.31) 0.917 
8-14 days 3112 41 (1.3) 1.08 1.21 (0.83 - 1.78) 0.316 
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Table 3. Baseline characteristics before and after propensity-score matching of men 
prescribed three versus seven days of antibiotics. Values are numbers (%) unless 
otherwise stated. *SMD = standardised mean difference 
 
Before matching After matching 
3 days 7 days SMD* 3 days  7 days SMD* 
Number (%) of prescriptions 2498 (7.7) 20729 (63.6)  2394 (25.0) 7182 (75.0)  
Mean (SD) age 77.4 (8.0) 76.9 (7.9) 0.071 77.5 (8.0) 77.4 (8.0) 0.008 
Antibiotic choice 
Amoxicillin 
Cefalexin 
Ciprofloxacin 
Co-amoxiclav 
Nitrofurantoin 
Trimethoprim 
 
12 (0.5) 
60 (2.4) 
38 (1.5) 
13 (0.5) 
241 (9.6) 
2134 (85.4) 
 
1392 (6.7) 
1133 (5.5) 
649 (3.1) 
1843 (8.9) 
3301 (16.0) 
12411 (60.0) 
 
-0.887 
-0.202 
-0.127 
-1.141 
-0.217 
0.727 
 
12 (0.5) 
57 (2.4) 
38 (1.6) 
13 (0.5) 
231 (9.6) 
2043 (85.3) 
 
39 (0.5) 
166 (2.3) 
109 (1.5) 
36 (0.5) 
703 (9.8) 
6129 (85.3) 
 
-0.006 
0.005 
0.006 
0.006 
-0.005 
0.000 
IMD decile 
1 or 2 (least deprived)  
3 or 4 
5 or 6 
7 or 8 
9 or 10 (most deprived) 
 
527 (21.1) 
552 (22.1) 
599 (24.0) 
427 (17.1) 
393 (15.7) 
 
5217 (25.2) 
5016 (24.2) 
4568 (22.0) 
3437 (16.6) 
2491 (12.0) 
 
 
 
 
 
0.147 
 
498 (20.8) 
529 (22.1) 
578 (24.1) 
408 (17.0) 
381 (15.9) 
 
1497 (20.8) 
1545 (21.5) 
1703 (23.7) 
1368 (19.0) 
1069 (14.9) 
 
 
 
 
 
0.000 
Housebound 101 (4.0) 641 (3.1) 0.052 100 (4.2) 296 (4.1) 0.003 
Respiratory disease 478 (19.1) 3934 (19.0) 0.002 460 (19.2) 1371 (19.1) 0.003 
Cardiac failure 178 (7.1) 1365 (6.6) 0.025 178 (7.4) 527 (7.3) 0.004 
Dementia 160 (6.4) 1080 (5.2) 0.044 151 (6.3) 469 (6.5) -0.009 
Peripheral vascular disease 218 (8.7) 1695 (8.2) 0.018 213 (8.9) 622 (8.7) 0.008 
Renal disease 620 (24.8) 4758 (23.0) 0.047 618 (25.8) 1764 (24.6) 0.029 
Rheumatoid arthritis 47 (1.9) 374 (1.8) -0.002 44 (1.8) 129 (1.8) 0.003 
Cancer 486 (19.5) 4225 (20.4) -0.022 476 (19.9) 1408 (19.6) 0.007 
Stroke 320 (12.8) 2542 (12.3) 0.023 319 (13.3) 935 (13.0) 0.009 
Diabetes 576 (23.1) 4659 (22.5) 0.020 576 (24.1) 1692 (23.6) 0.012 
Liver disease 17 (0.7) 122 (0.6) 0.016 17 (0.7) 51 (0.7) 0.000 
Ischaemic heart disease 674 (27.0) 5347 (25.8) 0.028 667 (27.9) 1983 (27.6) 0.006 
Urinary catheter 182 (7.3) 1783 (8.6) -0.053 174 (7.3) 498 (6.9) 0.013 
Urinary incontinence 184 (7.4) 1393 (6.7) 0.018 175 (7.3) 512 (7.1) 0.007 
Polypharmacy 1048 (42.0) 7859 (37.9) 0.086 1033 (43.1) 3080 (42.9) 0.005 
Prostatic hyperplasia 760 (30.4) 6341 (30.6) -0.006 743 (31.0) 2138 (29.8) 0.027 
Prostate cancer 213 (8.5) 2071 (10.0) -0.056 207 (8.6) 618 (8.6) 0.002 
eGFR 
60-90 
45-59 
30-44 
15-29 
<15 
missing 
 
1569 (62.8) 
514 (20.6) 
223 (8.9) 
69 (2.8) 
19 (0.8) 
104 (4.2) 
 
13573 (65.5) 
4101 (19.8) 
1735 (8.4) 
478 (2.3) 
74 (0.4) 
768 (3.7) 
 
 
 
 
 
 
0.064 
 
1569 (65.5) 
514 (21.5) 
223 (9.3) 
69 (2.9) 
19 (0.8) 
0 (0) 
 
4740 (66) 
1558 (21.7) 
685 (9.5) 
172 (2.4) 
27 (0.4) 
0 (0) 
 
 
 
 
 
 
0.029 
Charlson score 
0 
1 
2 
3 
4 
5 
≥6 
 
657 (26.3) 
484 (19.4) 
512 (20.5) 
334 (13.4) 
219 (8.8) 
141 (5.6) 
151 (6.0) 
 
5819 (28.1) 
4067 (19.6) 
3958 (19.1) 
2881 (13.9) 
1759 (8.5) 
1131 (5.5) 
1114 (5.4) 
 
 
 
 
 
 
 
0.045 
 
594 (24.8) 
463 (19.3) 
499 (20.8) 
328 (13.7) 
218 (9.1) 
141 (5.9) 
151 (6.3) 
 
1894 (26.4) 
1385 (19.3) 
1423 (19.8) 
1003 (14) 
623 (8.7) 
425 (5.9) 
429 (6.0) 
 
 
 
 
 
 
 
0.027 
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Table 4. Odds ratios and 95% CIs for each outcome in men matched on their propensity to receive a seven-day antibiotic prescription.   
 
 
7 day prescriptions 3 day prescriptions 
  
Outcome Number (%) of events Number (%) of events OR (95% CI)* p-value 
Re-consultation and re-prescription within 14 days 399 (5.6) 192 (8.0) 1.52 (1.25 - 1.85) <0.001 
Hospitalised for UTI within 14 days 209 (2.9) 59 (2.5) 0.81 (0.61 - 1.09) 0.179 
Hospitalised for sepsis within 14 days 18 (0.3) 4 (0.2) 0.60 (0.20 - 1.75) 0.350 
Hospitalised for AKI within 14 days 131 (1.8) 29 (1.2) 0.62 (0.42 - 0.93) 0.021 
Death within 28 days 96 (1.3) 36 (1.5) 1.07 (0.73 - 1.57) 0.729 
 
*Reference = 7 day prescription
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Figure legends 
Figure 1. Flow of men from initial identification in the database to final cohort. 
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Figures 
 
Figure 1. 
 
 
 
 
360,640 men ≥65 years old between 1st January 2010 and 31st December 2016 with 
data of the required quality and eligible for data linkage. 
348,981 men eligible for inclusion. 
33,745 men had a record indicating a UTI 
32,593 men entered into the final cohort. 
UTI events where antibiotic duration missing (29), >14 days 
(750), or unreliable (373).  
Men with temporary registrations or gaps in their data 
coverage (11,659). 
Men without a record indicating a UTI (315,236) 
